Cutting edge: Lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation

Journal of Immunology

Volumn 184, Issue 2, 2010, Pages 535-539

  Dietrich, Tina ^a,b   Bock, Felix ^a,c   Yuen, Don ^d   Hos, Deniz ^a   Bachmann, Björn O ^a   Zahn, Grit ^e   Wiegand, Stanley ^f   Chen, Lu ^d   Cursiefen, Claus ^a,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Jerini AG   (Germany)

^f REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; JSM6427 ANTIBODY; MF4 31C1 ANTIBODY; UNCLASSIFIED DRUG; ALPHA5 INTEGRIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BLOOD VESSEL; C57BL 6 MOUSE; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA TRANSPLANTATION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; LYMPH VESSEL; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; VASCULARIZATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HISTOCOMPATIBILITY; IMMUNOLOGY; METHODOLOGY;

ANIMALS; BLOOD VESSELS; CORNEAL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; INTEGRIN ALPHA5; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; MICE, INBRED BALB C; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSPLANTATION IMMUNOLOGY;

EID: 76249095735     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903180     Document Type: Article

References (26)

1. Lechler, R. I., M. Sykes, A. W. Thomson, and L. A. Turka. 2005. Organ transplantation - how much of the promise has been realized? Nat. Med. 11: 605-613.
2. Kaplan, H. J., J. W. Streilein, and T. R. Stevens. 1975. Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells. J. Immunol. 115: 805-810.
3. Kerjaschki, D., N. Huttary, I. Raab, H. Regele, K. Bojarski-Nagy, G. Bartel, S. M. Kröber, H. Greinix, A. Rosenmaier, F. Karlhofer, et al. 2006. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat. Med. 12: 230-234.
4. Yamamoto, I., Y. Yamaguchi, H. Yamamoto, T. Hosoya, S. Horita, K. Tanabe, S. Fuchinoue, S. Teraoka, and H. Toma. 2006. A pathological analysis of lymphatic vessels in early renal allograft. Transplant. Proc. 38: 3300-3303.
5. Stuht, S., W. Gwinner, I. Franz, A. Schwarz, D. Jonigk, H. Kreipe, D. Kerjaschki, H. Haller, and M. Mengel. 2007. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies. Am. J. Transplant. 7: 377-384.
6. Jonigk, D., U. Lehmann, S. Stuht, M. Wilhelmi, A. Haverich, H. Kreipe, and M. Mengel. 2007. Recipient-derived neoangiogenesis of arterioles and lymphatics in quilty lesions of cardiac allografts. Transplantation 84: 1335-1342.
7. Geissler, H. J., A. Dashkevich, U. M. Fischer, J. W. Fries, F. Kuhn-Régnier, K. Addicks, U. Mehlhorn, and W. Bloch. 2006. First year changes of myocardial lymphatic endothelial markers in heart transplant recipients. Eur. J. Cardiothorac. Surg. 29: 767-771.
8. Cursiefen, C., J. Cao, L. Chen, Y. Liu, K. Maruyama, D. Jackson, F. E. Kruse, S. J. Wiegand, M. R. Dana, and J. W. Streilein. 2004. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 45: 2666-2673.
9. Küchle, M., C. Cursiefen, N. X. Nguyen, A. Langenbucher, B. Seitz, H. Wenkel, P. Martus, and G. O. Naumann. 2002. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch. Clin. Exp. Ophthalmol. 240: 580-584.
10. Dietrich, T., J. Onderka, F. Bock, F. E. Kruse, D. Vossmeyer, R. Stragies, G. Zahn, and C. Cursiefen. 2007. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am. J. Pathol. 171: 361-372.
11. Okazaki, T., A. Ni, O. A. Ayeni, P. Baluk, L. C. Yao, D. Vossmeyer, G. Zischinsky, G. Zahn, J. Knolle, C. Christner, and D. M. McDonald. 2009. alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation. Am. J. Pathol. 174: 2378-2387.
12. Bock, F., J. Onderka, T. Dietrich, B. Bachmann, B. Pytowski, and C. Cursiefen. 2008. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch. Clin. Exp. Ophthalmol. 246: 115-119.
13. Streilein, J. W., D. Bradley, Y. Sano, and Y. Sonoda. 1996. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest. Ophthalmol. Vis. Sci. 37: 413-424.
14. Stragies, R., F. Osterkamp, G. Zischinsky, D. Vossmeyer, H. Kalkhof, U. Reimer, and G. Zahn. 2007. Design and synthesis of a new class of selective integrin alpha5beta1 antagonists. J. Med. Chem. 50: 3786-3794.
15. Sano, Y., B. R. Ksander, and J. W. Streilein. 1995. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest. Ophthalmol. Vis. Sci. 36: 2176-2185.
16. Sonoda, Y., and J. W. Streilein. 1992. Orthotopic corneal transplantation in mice - evidence that the immunogenetic rules of rejection do not apply. Transplantation 54: 694-704.
17. Cursiefen, C., L. Chen, L. P. Borges, D. Jackson, J. Cao, C. Radziejewski, P. A. D'Amore, M. R. Dana, S. J. Wiegand, and J. W. Streilein. 2004. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113: 1040-1050.
18. Cursiefen, C., S. Ikeda, P. M. Nishina, R. S. Smith, A. Ikeda, D. Jackson, J. S. Mo, L. Chen, M. R. Dana,B. Pytowski, et al. 2005. Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am. J. Pathol. 166: 1367-1377.
19. Tammela, T., G. Zarkada, E. Wallgard, A. Murtomäki, S. Suchting, M. Wirzenius, M. Waltari, M. Hellström, T. Schomber, R. Peltonen, et al. 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-660.
20. Maguire, M. G., W. J. Stark, J. D. Gottsch, R. D. Stulting, A. Sugar, N. E. Fink, and A. Schwartz; Collaborative Corneal Transplantation Studies Research Group. 1994. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology 101: 1536-1547.
21. Sonoda, Y., Y. Sano, B. Ksander, and J. W. Streilein. 1995. Characterization of cellmediated immune responses elicited by orthotopic corneal allografts in mice. Invest. Ophthalmol. Vis. Sci. 36: 427-434.
22. Sonoda, Y., and J. W. Streilein. 1993. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J. Immunol. 150: 1727-1734. (Pubitemid 23129648)
23. Slegers, T. P., R. van der Gaag, N. van Rooijen, G. van Rij, and J. W. Streilein. 2003. Effect of local macrophage depletion on cellular immunity and tolerance evoked by corneal allografts. Curr. Eye Res. 26: 73-79.
24. Slegers, T. P., N. van Rooijen, G. van Rij, and R. van der Gaag. 2000. Delayed graft rejection in pre-vascularised corneas after subconjunctival injection of clodronate liposomes. Curr. Eye Res. 20: 322-324.
25. Yamagami, S., and M. R. Dana. 2001. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest. Ophthalmol. Vis. Sci. 42: 1293-1298.
26. Yamagami, S., M. R. Dana, and T. Tsuru. 2002. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 21: 405-409.